The U.S. Food and Drug Administration (FDA) has approved the first mRNA-based influenza vaccine. This decision introduces a new type of flu shot to the American public.
Developed by Moderna, the newly approved vaccine utilizes messenger RNA technology, a method previously used in COVID-19 vaccines. This marks a significant advancement in flu prevention.
The approval represents a pivotal moment for vaccine development, bringing a novel approach to combating seasonal influenza. This is a developing story and will be updated as details emerge.
